Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb

Avapro, Plavix patent expirations hurt results

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb
 
4Q Revenues: $4.2 billion (-23%)

4Q Earnings: $924 million (-25%)

YTD Revenues: $17.6 billion (-17%)

YTD Earnings: $2.5 billion (-52%)

Comments: U.S. sales decreased 38% to $2.2 billion in the quarter due to patent expirations for Avapro/Avalide in March 2012 and Plavix in May 2012. International sales were up 6% to $2.0 billion. Plavix sales were down 97% to $49 million. Avapro/Avalide sales were down 57% to $84 million. Abilify sales were up 11% to $819 million. Sprycel sales were up 24% to $281 million. Yervoy sales were up 47% to $211 million. Orencia sales were up 26% to $325 million. Onglyza/Kombiglyze sales were $198 million, up 29%. R&D expenses increased 7% to $1.1 billion in the quarter.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters